Visual outcomes of acute bacterial endophthalmitis treated with adjuvant intravitreal dexamethasone: A meta-analysis and systematic review

Christa Soekamto, Luca Rosignoli, Christopher Zhu, Daniel A Johnson, Jeong-Hyeon Sohn, Sepehr Bahadorani

Adjunctive treatment of bacterial endophthalmitis with intravitreal steroids is a topic of controversy among many ophthalmologists. The objective of this study is to evaluate the effects of intravitreal dexamethasone on the visual outcomes of patients with acute bacterial endophthalmitis through a systematic review and meta-analysis. A literature search of PubMed, Scopus, and Cochrane Library databases was performed to include studies on the visual outcomes of adjuvant intravitreal dexamethasone in patients with acute bacterial endophthalmitis. The review is based on the Preferred Reporting Items for Systematic review and Meta-Analysis (PRISMA) protocol. A total of 1545 articles met our search criteria and after further review, two randomized controlled trials and three retrospective case series were included in the final analysis. A total of 126 eyes were treated with intravitreal dexamethasone combined with antibiotics, and another 139 eyes were treated with antibiotics alone. All cases of endophthalmitis were post-operative and without intravitreal injection, with pooled results demonstrating no visual benefit with supplementation of intravitreal dexamethasone. Our meta-analysis does not show any visual benefit from steroid supplementation and yet, considering a relatively small number of patients included in each study, larger randomized controlled trials are required to further clarify the role of steroids in the treatment of acute bacterial endophthalmitis.

Key words: Antibiotics, endophthalmitis, steroid

Endophthalmitis is a vision-threatening condition with varied causes, including surgical intervention, trauma, systemic infection, corneal ulcer, bleb-associated infection, and intravitreal injection. Early signs and symptoms of endophthalmitis include decreased vision, pain, red eye, hypopyon, and hazy media. Prompt treatment is necessary to reduce vision loss. The incidence of endophthalmitis remains low at 0.04% following cataract surgery. Standard treatment of endophthalmitis is based on the landmark Endophthalmitis Vitrectomy Study (EVS) published in 1995. The authors in the EVS study evaluated 420 patients diagnosed with endophthalmitis related to cataract surgery or secondary intraocular lens implantation and treated with systemic antibiotics and intravitreal amikacin and vancomycin. The authors concluded that the use of systemic antibiotics resulted in no difference in final visual acuity (VA). Additionally, patients who presented with light perception (LP) vision had improved visual outcomes with core vitrectomy rather than vitreous tap and injection alone.

All patients in this study received oral prednisone 30 mg twice daily for 5–10 days. The study, however, did not address the potential use of intravitreal steroids in the treatment of acute bacterial endophthalmitis following cataract surgery.

The mechanisms of intraocular damage in bacterial endophthalmitis are attributed to multiple etiologies, including bacterial release of inflammatory toxins, bacterial enzymes causing damage to ocular tissues, and the host immune response. Thus, given the eye’s robust inflammatory response in endophthalmitis, some investigators have supported the use of steroids in addition to antibiotics to enhance the final visual outcome. Additionally, steroids have been shown to play a role in treating bacterial meningitis by decreasing morbidity and mortality via stabilization of the blood–brain barrier, which is thought to have similar functions to the blood–retina barrier. Nevertheless, considering that the side effects of systemic steroids are extensive, intravitreal use of dexamethasone is sometimes a preferred option. At the same time, controversy remains over the potential benefits of this treatment modality. In the present study, we performed a meta-analysis of prior studies to evaluate the potential visual benefits of dexamethasone supplementation to intravitreal antibiotics in the treatment of acute bacterial endophthalmitis.

Methods

Data sources
Our study was conducted in accordance with the Preferred Reporting Items for Systematic review and Meta-Analysis (PRISMA) protocol. A total of 1545 articles met our search criteria and after further review, two randomized controlled trials and three retrospective case series were included in the final analysis. A total of 126 eyes were treated with intravitreal dexamethasone combined with antibiotics, and another 139 eyes were treated with antibiotics alone. All cases of endophthalmitis were post-operative and without intravitreal injection, with pooled results demonstrating no visual benefit with supplementation of intravitreal dexamethasone. Our meta-analysis does not show any visual benefit from steroid supplementation and yet, considering a relatively small number of patients included in each study, larger randomized controlled trials are required to further clarify the role of steroids in the treatment of acute bacterial endophthalmitis.

For reprints contact: WKHLRPMedknow_reprints@wolterskluwer.com

Cite this article as: Soekamto C, Rosignoli L, Zhu C, Johnson DA, Sohn JH, Bahadorani S. Visual outcomes of acute bacterial endophthalmitis treated with adjuvant intravitreal dexamethasone: A meta-analysis and systematic review. Indian J Ophthalmol 2022;70:2835-41.
Meta-Analysis (PRISMA) protocol [see PRISMA checklist in file 1]. A systematic search was conducted through the PubMed, Scopus, and Cochrane Library databases by using the search terms “endophthalmitis” AND “dexamethasone” from the date of database inception to December 2020. The Scopus database was accessed through the University of Texas Health Science Center San Antonio (UTHSCSA) library.

Selection criteria
Eligible articles included studies comparing final visual acuity outcomes of patients who received intravitreal antibiotics alone versus those given adjuvant intravitreal dexamethasone in the setting of postoperative or post-intravitreal injection endophthalmitis. The outcome evaluated in our study was final visual acuity, which was converted into logMAR acuities for quantitative analysis based on Snellen vision. Articles met inclusion criteria if the study included acute endophthalmitis cases due to intraocular surgery of any type (cornea, glaucoma, cataract, and vitrectomy) or post-intravitreal injection of medications. The type of intravitreal antibiotics used and the performance of the vitrectomy procedure were not considered as limiting factors for inclusion of studies in our meta-analysis. Excluded articles included reviews, animal experiments, case reports, and letters. Additional studies excluded, as detailed in supplementary Table 1, were those that included the use of systemic steroids, non-English articles, fungal endophthalmitis, chronic endophthalmitis, endophthalmitis due to other etiologies (trauma, suture removal, stitch abscess, endogenous, and corneal ulcer), lack of final visual acuity outcomes, or incomplete data required for statistical analysis.[17-18,20,23-31] Two authors (CS and CZ) independently reviewed each title and/or abstract and eliminated studies based on the eligibility criteria. Subsequently, the studies were further narrowed by a review of the full-text articles. Discrepancies of eligible articles were discussed and resolved between the authors (CS and SB).

Data extraction
To avoid bias in the study, two authors (CS and CZ) independently extracted the raw data from the selected studies and a checklist was used to record the following information: first author, year of publication, study location, study design, sample size, intravitreal antibiotics and dose, and follow-up time. The primary outcome was final visual acuity (VA). When the mean final visual acuity and standard deviation could not be obtained from the study, the authors reached out to the corresponding authors via email to obtain the raw data, for which Moisseiev et al. (2017) has kindly provided their raw data for our data analysis. Etiologies of endophthalmitis other than post-operative or post-intravitreal injection were excluded from the analysis.[4] Considering that the selected studies had discrepancy in chart conversion of visual acuities of count finger or worse, the authors decided to minimize bias by normalizing visual outcomes of these studies with the following logMAR equivalents: count fingers (CF) as 1.8, hand motion (HM) as 2.3, light perception (LP) as 2.8, and no light perception (NLP) as 3.[7] Any disagreements were resolved through discussion between the authors (SB and CS).

Quality assessment
The risk of bias from the included randomized controlled studies was assessed by two authors by using the Cochrane risk of bias Table in the following seven domains: random sequence generation (selection bias), allocation concealment (selection bias), blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), selective reporting (reporting bias), and other potential sources of bias.[8] Pending the degree of adequacy in each domain, the risk of bias was judged as low (adequate), high (inadequate), or unclear (not enough information available). Egger’s and Begg’s tests were not carried out due to a relatively small number of selected studies.

Statistical analysis
RevMan 5.4 software was used for all our statistical analyses, including calculation of inverse variance and 95% confidence interval of final visual acuity (VA) by using the random-effect model. The same software was also used for graphing the forest plot and assessment of statistical heterogeneity by using the Chi-square test.

| First Author, Year | Location, Type of Study                  | n  | Antibiotics ± dexamethasone                                                                 | Primary outcome                        |
|--------------------|-----------------------------------------|----|-------------------------------------------------------------------------------------------|----------------------------------------|
| Manning et al.,[6] 2018 | Netherlands, Randomized controlled trial | 81 | Vancomycin 0.2 mg/0.1 mL Gentamicin 0.05 mg/0.1 mL Dexamethasone 400 µg/0.1 mL | BCVA at 12 months                      |
| Gan et al.,[10] 2005 | Netherlands, Randomized controlled trial | 13 | Vancomycin 0.2 mg/0.1 mL Gentamicin 0.05 mg/0.1 mL Dexamethasone 400 µg/0.1 mL | VA at 3 months, 12 months             |
| Miller et al.,[11] 2004 | USA, Retrospective case series          | 10 | Vancomycin 1.0 mg/0.1 mL Ceftazidime 2.25 mg/0.1 mL Amikacin 0.4 mg/0.1 mL Gentamicin 0.1 mg/0.1 mL Tobramycin 0.1 mg/0.1 mL Dexamethasone 400 µg/0.1 mL | VA at 6 months and antibiotic sensitivities |
| Eifrig et al.,[12] 2003 | USA, Retrospective case series          | 7  | Vancomycin Ceftazidime Gentamicin Tobramycin Dexamethasone (no doses provided) | Final VA and rate of enucleation or evisceration |
| Moisseiev et al.,[6] 2017 | USA, Retrospective chart review        | 15 | Vancomycin 1.0 mg/0.1 mL Ceftazidime 2.25 mg/0.1 mL Dexamethasone 400 µg/0.1 mL | Improvement in VA and final VA |

Total | 126 | 139 |
Results

Overall characteristics of included studies
A total of 1545 articles met our initial search criteria, and after further review of the inclusion/exclusion criteria, two randomized clinical trials and three retrospective case series were selected for our final analysis. A flowchart illustrating our literature selection process is displayed in Fig. 1. Two randomized studies specifically analyzed cases of endophthalmitis following cataract surgery, 167 cases by Manning et al. (2018), and 29 cases by Gan et al. (2005). The other studies included endophthalmitis due to various etiologies; thus, we extracted the data pertaining to post-surgical and post-intravitreal injection etiologies only. Thus, our meta-analysis included a total of 265 endophthalmitis cases, where 126 patients received treatment with dexamethasone (400 µg/0.1 mL) plus antibiotics, while 139 cases received intravitreal antibiotics alone [refer to Table 1 for details]. The dosage of dexamethasone was the same in all studies. However, one study (Eifrig et al. 2003) did not specify the dose. As summarized in Table 1, various antibiotics were used, which included vancomycin, gentamicin, ceftazidime, amikacin, and tobramycin. The primary outcome among all studies included final visual acuity.

Bias assessment
The included randomized controlled studies used random allocation of study participants into the intervention and control groups. The article by Gan et al. (2005) does not state whether a blinding process was used in the study, whereas the study by Manning et al. (2018) employed a double-blind approach. Gan’s study had to be terminated early as the dexamethasone formulation became unavailable during the investigation. Overall, the authors of this review believe Manning’s study to be at low risk of publication bias, whereas Gan’s study has unclear risk of publication bias as listed in Table 1.

Study outcomes and pooled results
Of the randomized controlled studies, Manning et al. (2018) reported a statistically insignificant difference in final VA between the dexamethasone and placebo groups (P = 0.90), whereas Gan et al. (2005) reported a trend toward better visual outcomes at 3 and 12 months in the dexamethasone group without reaching statistical significance (3 months: P = 0.055, 12 months: P = 0.080). When using our own logMAR conversion for poor visual acuities, the mean BCVA at 12 months in Manning’s study was 0.65 ± 1.03 for the dexamethasone group and 0.74 ± 1.1 for the control group. For Gan’s study, the mean LogMAR acuities were 0.77 ± 0.70 and 1.27 ± 1.04 for the dexamethasone and control group, respectively. For both studies, the control group included antibiotic supplementation along with a placebo injection. As illustrated in Fig. 3, the inverse variance of the mean difference was ~0.09 for Manning et al. (2018) and ~0.50 for Gan et al. (2005), which is roughly equivalent to 5 and 25 Early Treatment Diabetic Retinopathy Study (ETDRS) letters, respectively. This difference, however, did not reach a statistical significance (P = 0.27).
as demonstrated in Fig. 3A forest plot. Similarly, inclusion of the nonrandomized (Miller et al. 2004, Eifrig et al. 2003, and Moisseiev et al. 2017) studies did not change the conclusion of our meta-analysis as there was no significant difference between the dexamethasone-supplemented group compared to antibiotics alone ($P = 0.87$) in Fig. 3B.\[6,11,12\]

It is worth noting that for Manning et al. (2018) study, cultures that grew gram-negative bacteria or gram-positive organisms other than coagulase-negative staphylococci were more likely to lead to light perception vision or evisceration.\[9\] Meanwhile, those infected by coagulase-negative staphylococci were more likely to have better visual outcomes, with $93\%$ of visual acuities ranging from logMAR 0.0 to logMAR 0.7 (Snellen equivalent of 20/20 to 20/100). Gan et al. 2005, on the other hand, reports that most patients grew *S. epidermidis* with final visual acuity ranging from logMAR 0.15 to logMAR 2.8 (Snellen equivalent of 20/30 to LP).\[10\]

**Subgroup analysis for pars plana vitrectomy**

To understand the role of dexamethasone in patients undergoing pars plana vitrectomy (PPV), we performed a subgroup analysis of the Eifrig et al. (2003), Miller et al. (2004), and Gan et al. (2005) articles, where a number of patients received PPV.\[10,11,12\] However, due to a small number of patients undergoing PPV in some of the selected articles, aggregate data meta-analysis could not be performed. Instead, we conducted an individual participant meta-analysis by compiling data from these three articles. Our analysis demonstrates that visual acuity (sample size, Mean ± SD) was not significantly different between dexamethasone (14, 2.13 ± 1.17) and the control (9, 1.83 ± 1.18) groups. Similarly, subgroup analysis of the results from Gan et al. (2005), Manning et al. (2018), and Moisseiev et al. (2017) demonstrates that supplementation with dexamethasone does not affect the final visual outcome ($P = 0.99$) in patients that did not receive PPV [Fig. 4].\[6,9,10\] Of note, none of the patients in Manning et al. (2018) and Moisseiev et al. (2017) studies had undergone PPV.\[6,9\]

**Discussion**

Endophthalmitis due to bacterial infection leads to the release of toxins along with the host inflammatory response, which could irreversibly damage the retina.\[3\] Thus, some investigators have supported the use of steroids to limit this response and improve visual outcomes in endophthalmitis. Nevertheless, controversy regarding the use of intravitreal steroids exists due to concerns of vulnerability to fungal infections, sequestration of neutrophils necessary for eliminating infection, retinal toxicity, and its effects on the pharmacokinetics of intravitreal antibiotics.\[14\] Our meta-analysis shows that final visual outcomes were not improved in acute bacterial endophthalmitis patients receiving intravitreal dexamethasone. However, the limited number of samples and studies suggests the need for more prospective randomized studies to provide strong and convincing evidence of any potential effects, whether harmful or beneficial.

In a study by Meredith et al. (1996),\[15\] rabbit models with *Staphylococcus aureus* endophthalmitis demonstrated worse inflammatory scores, more corneal opacities, and retinal necrosis when treated with intraocular dexamethasone. Another animal study by Kim et al. (1996)\[16\] revealed no beneficial effect when adding intravitreal dexamethasone to ciprofloxacin in rabbits with *Pseudomonas aeruginosa* endophthalmitis treated at 6 and 12 h, possibly due to impairment of the bactericidal effects of the antibiotics.

![Figure 2](image-url)  
**Figure 2:** Methodological quality of studies demonstrated by Cochrane risk of bias table as low risk of bias (+ symbol), high risk of bias (− symbol), or unclear risk of bias (? Symbol)
the same time, while some studies conclude that intravitreal steroids provide no benefit in either inflammatory or visual outcomes, there are also other studies that provide evidence of added benefit from steroid supplementation. A study by Das et al. (1999) suggested intravitreal dexamethasone provides benefits in early reduction of inflammation but no changes in visual acuity in the setting of endogenous endophthalmitis. Thus, these controversial results necessitate a systematic review of current literature to determine if the clinical use of intravitreal dexamethasone has any potential benefits in the treatment of patients with acute bacterial endophthalmitis. To address this question, our meta-analysis demonstrated that patients treated with dexamethasone did not have better visual outcomes.

To the best of our knowledge, currently, there is only one existing meta-analysis evaluating the effects of adjunctive steroids in the setting of acute endophthalmitis conducted by Kim et al. (2017). The authors of Kim et al.’s (2017) review concluded that the available evidence was insufficient to suggest the effectiveness of adjunctive dexamethasone. Notable differences between Kim et al.’s (2017) and our current meta-analysis include 1) exclusion of Albrecht et al. (2011) study due to grouped visual outcomes and inability to calculate mean final visual acuity with standard deviation; 2) exclusion of Das et al. (1999) study due to lack of final visual acuities (functional success was recorded if visual acuity was at least 6/120); 3) inclusion of Manning et al. (2018) randomized study; and 4) inclusion of retrospective studies (Eifrig et al. 2003; Miller et al. 2004). In addition, in our meta-analysis, we analyzed randomized studies alone versus all studies combined (randomized and retrospective). The former approach reduces the risk of bias, whereas the latter approach has a larger sample size with increased power of the analysis. However, both approaches yielded a similar outcome, where there was no statistical difference in visual outcome after supplementation of intravitreal dexamethasone. Lastly, our meta-analysis includes subgroup analysis of PPV patients, demonstrating no visual benefit from dexamethasone supplementation. Indeed, a similar conclusion was drawn by Das et al. (1999) randomized study, where dexamethasone supplementation did not affect the final visual outcome in patients with bacterial endophthalmitis treated with vitrectomy and intravitreal antibiotics. However, this study was excluded from our meta-analysis due to the lack of mean and standard deviation data for the visual acuity.

Figure 3: Forest plot showing the weighted mean difference of best-corrected visual acuity (BCVA) between endophthalmitis patients that received either dexamethasone [experimental] or placebo [control]. Note that values smaller than zero favor dexamethasone supplementation to intravitreal antibiotics, whereas values larger than zero favor injection of antibiotics with placebo. Panel A represents randomized studies. Panel B represents all studies (randomized and retrospective). [SD: standard deviation, IV: inverse variance, Random: Random-effect model, CI: confidence interval]

Figure 4: Forest plot of the weighted mean difference of best-corrected visual acuity (BCVA) for the subgroup of patients that did not receive Pars Plana Vitrectomy. No statistical significance is observed between the dexamethasone [experimental] or placebo [control] groups (P = 0.99). [SD: standard deviation, IV: inverse variance, Random: Random-effect model, CI: confidence interval]
It is worth noting that there is growing discussion among the retina community regarding a change in practice patterns and treating endophthalmitis with early vitrectomy. A recently published study by Soliman et al. (2019) explored international practice patterns for acute endophthalmitis secondary to intraocular surgery or intravitreal injections. In this retrospective study, a total of 57 retina specialists from 28 countries took part, totaling 253 cases of acute endophthalmitis. They concluded that as a practice pattern, early PPV within 1 week of presentation was performed frequently (74.3%) regardless of the presenting visual acuity. A follow-up study by this group then analyzed the visual outcomes of patients receiving intravitreal antibiotics alone versus early PPV. Their final conclusion was that visual outcomes were similar between the two groups. The most common gauges used were 23-G (63%), followed by 25 and 20-G vitrectors (23.5% and 13.4%, respectively). Although this was a necessary study exploring outcomes of endophthalmitis with smaller gauge vitrectors and modernized vitrectomy systems, this research provided evidence that early vitrectomy does not provide better visual outcomes. We believe this published report by Soliman et al. (2021) is proof that we may need other avenues to more successfully treat endophthalmitis patients.

Conclusion

Our meta-analysis demonstrates that intravitreal dexamethasone does not provide additional visual benefits to endophthalmitis patients. Nevertheless, considering a relatively small number of patients included in the selected studies, larger randomized studies are needed to further clarify the role of steroids in the treatment of acute bacterial endophthalmitis.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

1. Results of the Endophthalmitis Vitrectomy Study. A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Endophthalmitis Vitrectomy Study Group. Arch Ophthalmol 1995;113:1479-96.
2. Pershing S, Lum F, Hsu S, Kelly S, Chiang MF, Rich WL 3rd, et al. Endophthalmitis after Cataract Surgery in the United States: A report from the intelligent research in sight registry, 2013-2017 Ophthalmology 2020;127:151-8.
3. Astley R, Miller FC, Mursalin MH, Coburn PS, Callegan MC. An eye on *Staphylococcus aureus* toxins: Roles in ocular damage and inflammation. Toxins (Basel) 2019;11:356.
4. Gan IM, Ugahary LC, van Dissel JT, van Meurs JC. Effect of intravitreal dexamethasone on vitreous vancomycin concentrations in patients with suspected postoperative bacterial endophthalmitis. Graefes Arch Clin Exp Ophthalmol 2005;243:1186-9.
5. Yasir M, Goyal A, Bansal P, Sonthalia S. Corticosteroid adverse effects. Treasure Island (FL): StatPearls; 2021.
6. Moissieiev E, Abbassi S, Park SS. Intravitreal dexamethasone in the management of acute endophthalmitis: A comparative retrospective study. Eur J Ophthalmol 2017;27:67-73.
7. Bach M. Visual Acuity “Cheat Sheet” – High And Low Vision, 2017. Available from: https://michaelbach.de/sci/acuity.html. [Last accessed on 2020 Dec 07].
8. Sterne JAC, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ 2019;366:l4898.
9. Manning S, Ugahary LC, Lindstedt FW, Wubbels RJ, van Dissel JT, Jansen JTG, et al. A prospective multicentre randomised placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics. Acta Ophthalmol 2018;96:348-55.
10. Gan IM, Ugahary LC, van Dissel JT, Feron E, Peperkamp E, Veckeneer M, et al. Intravitreal dexamethasone as adjuvant in the treatment of postoperative endophthalmitis: A prospective randomized trial. Graefes Arch Clin Exp Ophthalmol 2005;243:1200-5.
11. Miller JJ, Scott IU, Flynn HW Jr, Smidy WE, Corey RP, Miller D. Endophthalmitis caused by Streptococcus pneumoniae. Am J Ophthalmol 2004;138:231-6.
12. Eifrig CW, Scott IU, Flynn HW Jr, Miller D. Endophthalmitis caused by pseudomonas aeruginosa. Ophthalmology 2003;110:1714-7.
13. Gregori NZ, Feuer W, Rosenfeld PJ. Novel method for analyzing snellen visual acuity measurements. Retina 2010;30:1046-50.
14. Ching Wen Ho D, Agarwal A, Lee CS, Chhablani J, Gupta V, Khatri M, et al. A review of the role of intravitreal corticosteroids as an adjuvant to antibiotics in infectious endophthalmitis. Ocul Immunol Inflamm 2018;26:461-8.
15. Meredith TA, Aguilar HE, Drews C, Sawant A, Gardner S, Wilson LA, et al. Intracocular dexamethasone produces a harmful effect on treatment of experimental *Staphylococcus aureus* endophthalmitis. Trans Am Ophthalmol Soc 1996;94:241-52; discussion 252-7.
16. Kim IT, Chung KH, Koo BS. Efficacy of ciprofloxacin and dexamethasone in experimental pseudomonas endophthalmitis. Korean J Ophthalmol 1996;10:8-17.
17. Hall EF, Scott GR, Musch DC, Zacks DN. Adjunctive intravitreal dexamethasone in the treatment of acute endophthalmitis following cataract surgery. Clin Ophthalmol 2008;2:139-45.
18. Das T, Jalali S, Gothwal VK, Sharma S, Naduvilath TJ. Intravitreal dexamethasone in exogenous bacterial endophthalmitis: Results of a prospective randomised study. Br J Ophthalmol 1999;83:1050-5.
19. Kim CH, Chen MF, Coleman AL. Adjunctive steroid therapy versus antibiotics alone for acute endophthalmitis after intraocular procedure. Cochrane Database Syst Rev 2017;2:CD001231.
20. Albrecht E, Richards JC, Pollock T, Cook C, Myers L. Adjunctive use of intravitreal dexamethasone in presumed bacterial endophthalmitis: A randomised trial. Br J Ophthalmol 2011;95:1385-8. doi: 10.1136/bjo.2010.187963. Epub 2011 Feb 2. PMID: 21289020.
21. Soliman MK, Gini G, Kuhn F, Iros M, Parolini B, Ozdek S, et al. Visual outcome of early vitrectomy and intravitreal antibiotics in acute postsurgical and postintravitreal injection endophthalmitis: European vitreo-retinal society endophthalmitis study group. International practice patterns for the management of acute postsurgical and postintravitreal injection endophthalmitis: European vitreo-retinal society endophthalmitis study report 1. Ophthalmol Retina 2019;3:461-7.
22. Soliman MK, Gini G, Kuhn F, Parolini B, Ozdek S, Adelman RA, et al. Visual outcome of early vitrectomy and intravitreal antibiotics in acute postsurgical and postintravitreal injection endophthalmitis: European vitreo-retinal society endophthalmitis study report two Retina 2021;41:423-30.
23. Conrady CD, Feist RM Jr, Vitale AT, Shakoor A. Long-term visual outcomes of endophthalmitis and the role of systemic steroids in addition to intravitreal dexamethasone. BMC Ophthalmol. 2020 May 6;20(1):181. doi: 10.1186/s12886-020-01449-2. PMID: 32375683; PMCID: PMC7201644.
24. Yannuzzi NA, Si N, Kelhan N, Kuriyan AE, Albini TA, Berrocal AM, Davis JL, Smiddy WE, Townsend J, Miller D, Flynn HW Jr. Endophthalmitis After Clear Corneal Cataract Surgery: Outcomes
However, the sensitivity of the fungi consensus difficult—more so because quantifying resolution follow-up protocols in previous studies make a uniform anatomical integrity during initial endophthalmitis. Steroids can be considered. Has been done to reduce the microbial load. Then, if the patient conundrum is to consider steroids once an initial dose of flare up intraocular pathogens. One way to approach this regarding the status of steroids, as steroids are believed to shorten the overall disease course. It is not well understood inflammation may help reduce the irreversible damage and intraocular tissues, especially the neurosensory retina, leads to severe inflammation and bystander damage to.

Over Two Decades. Am J Ophthalmol. 2017 Feb;174:155-159. doi: 10.1016/j.ajo.2016.11.006. Epub 2016 Nov 23. PMID: 27889501.

25. Jackson TL, Paraskevopoulos T, Georgalas I. Systematic review of 342 cases of endogenous bacterial endophthalmitis. Surv Ophthalmol. 2014 Nov-Dec;59(6):627-35. doi: 10.1016/j.survophthal.2014.06.002. Epub 2014 Jun 18. PMID: 25113611.

26. Lindstedt EW, Bennebroek CA, van der Werf DJ, Veckeneer M, Norel AO, Nielsen CC, Wubbels RJ, van Dissel JT, van Meurs JC. A prospective multicenter randomized placebo-controlled trial of dexamethasone as an adjuvant in the treatment of postoperative bacterial endophthalmitis: interim safety analysis of the study drug and analysis of overall treatment results. Graefes Arch Clin Exp Ophthalmol. 2014 Oct;252(10):1631-7. doi: 10.1007/s00417-014-2770-8. Epub 2014 Aug 10. PMID: 25107542.

27. Jacobs DJ, Pathengay A, Flynn HW Jr, Leng T, Miller D, Shi W. Intravitreal dexamethasone in the management of delayed-onset bleb-associated endophthalmitis. Int J Inflam. 2012;2012:503912. doi: 10.1155/2012/503912. Epub 2012 Jan 11. PMID: 22288020; PMCID: PMC3263617.

28. Rehak M, Blatz R, Wiedemann P, Meier P. Primäre vitrektomie mit intraokulärer antibiotikaapplikation bei akuter postoperativer endophthalmitis [Primary vitrectomy with intraocular antibiotic application in postoperative endophthalmitis]. Ophthalmologe. 2007 Nov;104(11):958-64. German. doi: 10.1007/s00347-007-1564-3. PMID: 17704921.

29. Yoder DM, Scott IU, Flynn HW Jr, Miller D. Endophthalmitis caused by Haemophilus influenzae. Ophthalmology. 2004 Nov;111(11):2023-6. doi: 10.1016/j.ophtha.2004.05.018. PMID: 15522367.

30. Shah GK, Stein JD, Sharma S, Sivalingam A, Benson WE, Regillo CD, Brown GC, Tasman W. Visual outcomes following the use of intravitreal steroids in the treatment of postoperative endophthalmitis. Ophthalmology. 2000 Mar;107(3):486-9. doi: 10.1016/s0161-6420(99)00139-6. PMID: 10711885.

31. Majji AB, Jalali S, Das T, Gopinathan U. Role of intravitreal dexamethasone in exogenous fungal endophthalmitis. Eye (Lond). 1999 Oct;13 (Pt 5):660-5. doi: 10.1038/eye.1999.179. PMID: 10696322.
| First Author, Year | Location, Type of Study | Reason for Exclusion |
|--------------------|-------------------------|----------------------|
| Conrady et al., 2020 | USA, Retrospective Analysis | Nearly all patients (>90%) received intravitreal dexamethasone, and authors do not distinguish data from patients who did and did not receive dexamethasone. Additionally, 19% of patients received oral steroids |
| Yannuzzi et al., 2017 | USA, Retrospective case series | Does not stratify visual outcomes between subjects who received intravitreal dexamethasone and those who did not. |
| Jackson et al., 2014 | United Kingdom, Systematic Review | Includes endogenous endophthalmitis |
| Lindstedt et al., 2014 | Netherlands, Randomized controlled trial | Does not stratify results between subjects who received dexamethasone vs no dexamethasone |
| Jacobs et al., 2012 | USA, Retrospective case series | Includes chronic endophthalmitis due to bleb-associated endophthalmitis (BAE). |
| Albrecht et al., 2011 | UK, Randomized controlled trial | Reports visual acuities as grouped visual outcomes or as lines of improvement. Unable to calculate the mean visual acuities with standard deviation from the provided data. |
| Hall et al., 2008 | USA, Retrospective case series | Some subjects received oral steroids, does not stratify results based on whether or not patients received oral steroids. |
| Rehak et al., 2007 | Germany, Retrospective analysis | All pts received intravitreal dexamethasone and some received systemic steroids. All also underwent vitrectomy |
| Yoder et al., 2004 | USA, Retrospective case series | 69% of cases (11/16) were delayed onset. |
| Shah et al., 2000 | USA, Retrospective comparative trial | Does not provide standard deviation of visual acuities between the dexamethasone and no dexamethasone groups. |
| Majji et al., 1999 | India, Retrospective analysis | Study includes fungal endophthalmitis only |
| Das et al., 1999 | India, Prospective randomized trial | Does not provide mean visual acuity with standard deviation. Defines functional success as visual acuity of at least 6/120. |